One more note on MCU - it is without doubt true that the treated arm had substantially(!) worse death/stroke rate than placebo. My guess is probably p value under 0.20 THE WRONG WAY:
a) This is in line with the concern that MI as measured by CK-MB is perhaps not the best endpoint?
b) This explains why the company isn't talking numbers of patients but instead confining itself to p values and reductions.
Note that having the 'remainder group' be substantially the wrong way is a danger sign. Not the kiss of death, but not good.
Market Data 
Markets 
AI
